| Literature DB >> 20622117 |
Sydney X Lu1, Amanda M Holland, Il-Kang Na, Theis H Terwey, Onder Alpdogan, Jhoanne L Bautista, Odette M Smith, David Suh, Christopher King, Adam Kochman, Vanessa M Hubbard, Uttam K Rao, Nury Yim, Chen Liu, Alvaro C Laga, George Murphy, Robert R Jenq, Johannes L Zakrzewski, Olaf Penack, Lindsay Dykstra, Kevin Bampoe, Lia Perez, Bruce Furie, Barbara Furie, Marcel R M van den Brink.
Abstract
Alloreactive T cells are crucial for graft-versus-host disease (GVHD) pathophysiology, and modulating their trafficking patterns has been efficacious in ameliorating experimental disease. We report in this paper that P-selectin, a glycoprotein found on resting and inflamed endothelium, is important for donor alloreactive T cells trafficking into GVHD target organs, such as the intestines and skin. Compared with wild-type (WT) recipients of allogeneic bone marrow transplantation, P-selectin(-/-) recipients exhibit decreased GVHD mortality and decreased GVHD of the skin, liver, and small bowels. This was associated with diminished infiltration of alloactivated T cells into the Peyer's patches and small bowels, coupled with increased numbers of donor T cells in the spleen and secondary lymphoid organs (SLOs). Surprisingly, however, donor T cells deficient for P-selectin glycoprotein ligand 1, the most well described P-selectin ligand, mediated GVHD similar to WT T cells and accumulated in SLO and target organs in similar numbers as WT T cells. This suggests that P-selectin may be required for trafficking into inflamed tissues but not SLO and that donor T cells may use multiple P-selectin ligands apart from P-selectin glycoprotein ligand 1 to interact with P-selectin and traffic into inflamed tissues during GVHD. We conclude that targeting P-selectin may be a viable strategy for GVHD prophylaxis or treatment.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20622117 PMCID: PMC3752704 DOI: 10.4049/jimmunol.0903148
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422